NextBio™ Addresses Fundamental Research Challenge With General Availability of Knowledge-based Discovery Platform
CUPERTINO, Calif.–(BUSINESS WIRE)–NextBio (http://www.nextbio.com) today announced the general availability of its first-of-a-kind, knowledge-based discovery platform. For nearly a year, scientists at leading research institutions have been using NextBio’s platform in diverse therapeutic areas to generate new hypotheses and advance research discovery. NextBio enables scientists to make novel discoveries by leveraging information across the entire organization and across an expanding reference database of carefully curated, large-scale public studies. With an interface that’s as easy to use as the most popular internet search engine, NextBio empowers any scientist to formulate complex questions across different assay platforms, data types, therapeutic areas and organisms to gain valuable scientific and clinical insights.
Among early access users are research and clinical scientists at Scripps Florida, UC Davis, Stanford University, Princeton University, Yale University, University of Florida, the Institute for Systems Biology, Genentech, Burnham Institute and Pioneer Hi-Bred International. With NextBio, scientists can quickly associate disease states with specific pathways and genes, identify compounds with a particular mechanism of action and profile target activity across a collection of tissue signatures.
“NextBio gives researchers a view of all the different experiments in its repository at once, so they’re able to come up with questions they wouldn’t have thought of before”, said Dr. Nick Tsinoremas, senior director of informatics at Scripps Florida. “NextBio is liberating for bench scientists because it empowers them with intuitive querying capabilities across multiple data sets without the need for bioinformatics expertise.”
“With NextBio, I can accomplish in a few minutes and with just a few clicks what previously took me months to do, and that’s if I could actually find all of the study results and bring them into one platform”, said Dr. Frank Sharp, Professor, UC Davis M.I.N.D. Institute. “I use NextBio to narrow down my experimental hypotheses before getting into the wet lab, and again to interpret my study results in the context of the large repository of information NextBio contains.”
NextBio was founded in 2004 by former executives from Silicon Genetics and ParaAllele BioScience. “For years, biopharmaceutical organizations have struggled with how to develop improved therapies from knowledge buried in the vast quantities of data generated in their own research labs and available through public sources”, said Saeid Akhtari, co-founder, president and CEO of NextBio. “NextBio addresses that challenge with an innovative platform that is immediately accessible to and facilitates novel insights for bench scientists, clinicians and bioinformatics experts alike.”
NextBio improves the research effectiveness and efficiency of individual researchers, and automatically scales to provide productivity gains throughout the enterprise. NextBio’s flexible repository integrates a wide variety of assay data types, facilitating collaboration among previously segregated research domains. Organizations can reuse and maximize the scientific value of information across projects, therapeutic areas and research silos, thereby increasing their return on investment in “omics” technologies.
The NextBio platform is offered exclusively by NextBio. For more information please visit http://www.nextbio.com.
About NextBio NextBio accelerates biological and clinical discovery by overcoming many of the challenges created by an overwhelming abundance of disparate, high-throughput experimental data. Founded in 2004 by a team of industry leaders, NextBio addresses a fundamental need within R&D organizations to effectively leverage vast quantities of internal and public information to advance research-critical discoveries. NextBio’s knowledge-based discovery platform enables all researchers to tap into the power of information combined from different assays, platforms and research silos to draw new scientific and clinical insights. Its value in improving research efficiency and effectiveness has already been proven at some of the world’s leading research organizations.
